For the Inventor, By the Inventor

Enter assignee name

Frankfurt am Main, Germany

Zentaris Ag

USPTO Granted Patents = 20

CIPO Patents = 1

Forward Citations = 198

Loading Chart...

Loading Chart...

68 inventors (with patents filed for the assignee):

Bernd Nickel (7 out of 27 patents)

Thomas Beckers (4 out of 36 patents)

Bernhard Kutscher (4 out of 45 patents)

4. Peter Emig (4 out of 29 patents)

5. Thomas Klenner (4 out of 11 patents)

6. Jürgen Engel (4 out of 15 patents)

7. Thomas Reissmann (3 out of 16 patents)

8. Eckhard Günther (3 out of 4 patents)

9. Peter Hilgard (3 out of 17 patents)

10. Siavosh Mahboobi (2 out of 5 patents)

11. Herwig Pongratz (2 out of 5 patents)

12. Norbert Schmees (2 out of 28 patents)

13. Eckhard Guenther (2 out of 16 patents)

14. Emmanuel Polymeropoulos (2 out of 24 patents)

15. Holger Hess-Stumpp (2 out of 13 patents)

20 patents: Sort by Forward Citations

1. 7378522 - Quinoline, isoquinoline and phthalazine derivatives as antagonists of the gonadotropin-releasing hormone (2008-05-27),

2. 7122570 - Tetrahydrocarbazol derivatives as ligands for G-protein-coupled receptors (GPCR) (2006-10-17),

3. 6890926 - Heteroaryl derivatives and their use as medicaments (2005-05-10),

4. 6863891 - Oligopeptide lyophilisate, their preparation and use (2005-03-08),

5. 6861409 - Growth hormone secretagogues (2005-03-01),

6. 6849715 - Agents useful for inactivation of Ras subfamily proteins (2005-02-01),

7. 6812243 - Indole derivatives and their use for the treatment of malignant and other diseases based on pathological proliferation (2004-11-02),

8. 6790858 - Quinoline, isoquinoline and phthalazine derivatives as antagonists of the gonadotropin-releasing hormone (2004-09-14),

9. 6727252 - Methods of modulating serine/threonine protein kinase function with 5-azaquinoxaline-based compounds (2004-04-27),

10. 6716817 - Method of treatment of female infertility (2004-04-06),

11. 6706722 - Heteroaryl derivatives and their use as medicaments (2004-03-16),

12. 6696428 - Use of dopamine receptor antagonists in palliative tumor therapy (2004-02-24),

13. 6638935 - Heteroary1 derivatives and their use as medicaments (2003-10-28),

14. 6627609 - LHRH antagonists having improved solubility properties (2003-09-30),

15. 6576624 - Use of dopamine receptor antagonists in palliative tumor therapy (2003-06-10),

Zentaris AG is a biopharmaceutical company focused on the development and commercialization of innovative treatments for various diseases. With a commitment to improving patient outcomes, Zentaris leverages its expertise in drug discovery and clinical development to bring novel therapies to market. With a diverse pipeline and a strong research and development team, Zentaris aims to address unmet medical needs and make a positive impact on global healthcare.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

20 Patents

#37 in Frankfurt am Main

#2,245 in Germany

#30,350 in the World

Frankfurt am Main, Germany

Zentaris Ag

Forward Citations = 198

68 inventors:

Bernd Nickel (7 out of 27 patents)

Thomas Beckers (4 out of 36 patents)

Bernhard Kutscher (4 out of 45 patents)

4. Peter Emig (4 out of 29 patents)

5. Thomas Klenner (4 out of 11 patents)

Please report any incorrect information to support@idiyas.com

Loading…